Every Form 4 that COGNITION THERAPEUTICS INC (CGTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGTX filings page.
Khattar Jack A. reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Jack A. Khattar received an equity award of 25,000 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock upon settlement. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholders’ meeting, contingent on his continued board service. Following this grant, Khattar directly holds 73,500 shares of common stock.
Monia Brett P reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Brett P. Monia received an award of 25,000 restricted stock units (RSUs). These RSUs represent a right to receive an equal number of common shares at no purchase price per share.
The RSUs vest in full on the earlier of June 17, 2027 or the date of the company’s next annual meeting of stockholders, as long as Monia continues to serve as a director through that date. Following this grant, Monia directly holds 73,500 shares of Cognition Therapeutics common stock.
Wallace Peggy reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics director Peggy Wallace received an equity grant tied to future stock. She was awarded 25,000 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest in full on the earlier of June 17, 2027, or the company’s next annual stockholder meeting, if she continues serving as a director. Following this grant, her directly held position reported in the filing is 111,461 shares. This is a compensation-related award rather than an open-market purchase.
Cognition Therapeutics director Ellen B. Richstone reported a grant of 25,000 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock upon settlement. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting, contingent on her continued board service. Following this equity award, she holds 83,500 shares of common stock directly. This Form 4 reflects a compensation-related acquisition rather than any open-market trading.
Fletcher Aaron G.L. reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Aaron G.L. Fletcher received an award of 25,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting, subject to his continued board service.
The filing shows 81,229 common shares held directly after the award, and additional indirect holdings through multiple Bios-affiliated investment funds. Under existing agreements, Fletcher holds certain equity awards as a nominee for BP Directors, LP, and various Bios and Cavu entities may be deemed indirect beneficial owners, while all reporting persons disclaim beneficial ownership beyond any pecuniary interest.
Cognition Therapeutics Inc. Chief Financial Officer John Brendan Doyle reported a routine tax-related share disposition. On the vesting of restricted stock units, the company withheld 8,567 shares of common stock at $1.28 per share to cover tax withholding obligations. After this non-market transaction, Doyle directly holds 618,942 shares of Cognition Therapeutics common stock, indicating he retains a substantial equity stake following the RSU vesting.
Cognition Therapeutics Chief Financial Officer John Brendan Doyle bought 10,000 shares of common stock in an open-market purchase at $1.13 per share. The transaction involved directly held shares. Following this purchase, Doyle directly owns a total of 627,509 shares of Cognition Therapeutics common stock.
Cognition Therapeutics Inc CEO and President Lisa Ricciardi reported an open-market purchase of 9,175 shares of common stock at $1.10 per share on April 16, 2026. After this transaction, she directly holds 1,715,851 shares and indirectly holds 38,851 shares through her spouse.
Cognition Therapeutics Inc. Chief Medical Officer Anthony Caggiano reported an open-market purchase of 10,000 shares of the company’s Common Stock on April 16, 2026 at a price of $1.11 per share. Following this transaction, his direct holdings increased to 874,906 shares of Common Stock.
Cognition Therapeutics CEO Lisa Ricciardi reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 5,850 shares of common stock at $1.12 per share to cover tax obligations. After this, she directly owns 1,706,676 shares, plus 38,851 shares held indirectly by her spouse.
COGNITION THERAPEUTICS INC Chief Financial Officer John Brendan Doyle reported a tax-related share disposition. On the vesting of restricted stock units, the issuer withheld 1,560 shares of common stock at $1.12 per share to cover tax obligations, leaving Doyle with 617,509 directly owned shares after the transaction.
COGNITION THERAPEUTICS INC Chief Medical Officer Anthony Caggiano reported a tax-related share disposition. On 2026-02-15, he had 4,680 shares of common stock withheld at $1.12 per share to cover tax obligations from vesting restricted stock units. After this tax-withholding transaction, he directly owned 864,906 shares of common stock.
Cognition Therapeutics CEO and President Lisa Ricciardi reported equity compensation and related tax withholding transactions in company stock. On February 3, 2026, she acquired 800,000 RSU-based shares of common stock at $0.00 per share, reflecting a stock award.
On the same day, the company withheld 26,036 shares at $1.12 to cover taxes tied to RSU vesting, and on February 4, 2026 withheld another 51,704 shares at $1.03 for the same purpose. After these transactions, she directly beneficially owned 1,712,526 shares, with an additional 38,851 shares held indirectly by her spouse.
Cognition Therapeutics (CGTX) Chief Financial Officer John Brendan Doyle reported equity compensation and related tax withholding transactions. On February 3, 2026, he acquired 200,000 shares of Common Stock at $0.00 per share, representing restricted stock units (RSUs), increasing his direct holdings to 645,990 shares.
On February 4, 2026, 26,921 shares of Common Stock were withheld at $1.03 per share to cover tax obligations tied to RSU vesting, leaving Doyle with 619,069 directly owned shares of Cognition Therapeutics Common Stock.
Cognition Therapeutics Chief Medical Officer Anthony Caggiano reported equity compensation and related tax withholding in company stock. On 02/03/2026, he acquired 400,000 shares of Common Stock at $0.00 per share, representing settlement of restricted stock units, each equal to one share of Common Stock upon vesting.
On the same date, 11,488 shares were withheld at $1.12 per share, and on 02/04/2026 a further 26,919 shares were withheld at $1.03 per share, to cover tax obligations tied to the RSU vesting. After these transactions, Caggiano directly owned 869,586 shares of Cognition Therapeutics Common Stock.
Insider transaction summary: Aaron G.L. Fletcher, a director and 10% owner of Cognition Therapeutics, acquired 7,729 shares (and a matching option) on 09/19/2025 at $0.84 per share. After this transaction he directly holds 56,229 shares, including 48,500 shares held as nominee for BP Directors under an agreement, and reports substantial indirect ownership through multiple Bios-related funds totaling several million shares across listed entities. The filing clarifies complex fund and advisor relationships and disclaims beneficial ownership except to the extent of pecuniary interest.